Candriam S.C.A. Reduces Position in Roivant Sciences Ltd. $ROIV

Candriam S.C.A. decreased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 19.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 2,001,976 shares of the company’s stock after selling 488,450 shares during the period. Candriam S.C.A.’s holdings in Roivant Sciences were worth $55,455,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. HighVista Strategies LLC raised its stake in shares of Roivant Sciences by 61.4% during the third quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock valued at $1,496,000 after acquiring an additional 37,590 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in Roivant Sciences by 790.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after purchasing an additional 2,052,693 shares in the last quarter. Capricorn Fund Managers Ltd grew its stake in Roivant Sciences by 124.4% in the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after purchasing an additional 247,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after purchasing an additional 3,254,113 shares during the period. Finally, Foursixthree Capital LP increased its holdings in Roivant Sciences by 4.2% during the 3rd quarter. Foursixthree Capital LP now owns 938,175 shares of the company’s stock worth $14,195,000 after purchasing an additional 38,175 shares during the period. Institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 12,380 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total transaction of $436,766.40. Following the sale, the director directly owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. The trade was a 0.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,345,687 shares of company stock worth $77,017,443 in the last three months. 10.80% of the stock is owned by company insiders.

Roivant Sciences Trading Down 2.3%

Shares of NASDAQ ROIV opened at $35.97 on Friday. The stock has a market capitalization of $25.87 billion, a PE ratio of -59.95 and a beta of 1.11. The stock’s fifty day simple moving average is $31.08 and its two-hundred day simple moving average is $27.74. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period last year, the business posted ($0.29) EPS. On average, equities analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ROIV. HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Citigroup raised their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Guggenheim lifted their price objective on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.